IP 2026 conclave in Haridwar drives pharma quality compliance push
Synopsis
India's pharmaceutical quality watchdog took its IP 2026 roadshow to Haridwar — one of the country's top drug-manufacturing belts — signalling a push to close the gap between updated pharmacopoeial standards and ground-level compliance. With Uttarakhand's pharma cluster in focus, the IPC is betting that direct industry engagement can translate new norms into consistent practice.
Key Takeaways
The Indian Pharmacopoeia Commission (IPC) held a scientific conclave on IP 2026 in Haridwar on 11 June 2025 .
The event was organised with the Association of Devbhumi Pharma Industries and affiliated Uttarakhand pharmaceutical associations.
Dr V Kalaiselvan , Secretary-cum-Scientific Director, IPC, highlighted key advancements in IP 2026 and stressed the need for active industry participation.
Uttarakhand is one of India's leading pharmaceutical manufacturing hubs, making it a priority state for IP compliance outreach.
Sessions covered microbiological quality requirements, reference substances, analytical investigations, and quality management systems.
The Indian Pharmacopoeia Commission (IPC), an autonomous body under the Ministry of Health and Family Welfare, convened a scientific conclave and interactive session on the Indian Pharmacopoeia (IP) 2026 in Haridwar on 11 June 2025, aimed at raising industry awareness of new pharmacopoeial provisions and strengthening quality compliance across India's pharmaceutical manufacturing sector.
Key Developments
The conclave was organised in collaboration with the Association of Devbhumi Pharma Industries and affiliated Uttarakhand pharmaceutical associations. It brought together a cross-section of stakeholders — manufacturers, quality control and assurance professionals, regulatory authorities, analytical scientists, and drug testing laboratory personnel — to deliberate on the latest developments in pharmacopoeial standards and their practical implementation.
Technical sessions covered a broad range of subjects, including recent updates to pharmacopoeial standards, reference substances, microbiological quality requirements, quality management systems, analytical investigations, and biological standards. Participants received hands-on insights into applying IP norms in day-to-day manufacturing and quality control operations.
What the IPC Said
Dr V Kalaiselvan, Secretary-cum-Scientific Director, IPC, underscored the IP's role in establishing scientifically validated quality benchmarks for medicines and reinforcing India's standing as a global pharmaceutical leader. He highlighted the key advancements incorporated in IP 2026 and called for active industry participation in ensuring effective implementation of pharmacopoeial requirements across the supply chain.
Why Uttarakhand Was Chosen
Uttarakhand is one of India's leading pharmaceutical manufacturing hubs and has been among the states that have effectively utilised the IP and Indian Pharmacopoeia Reference Substances to ensure the quality, safety, and efficacy of medicines. The conclave was specifically held in the state to further strengthen industry awareness, support compliance with pharmacopoeial requirements, and provide direct handholding support to local pharmaceutical manufacturers and other stakeholders.
What Happens Next
The event concluded with a networking session, enabling continued dialogue among regulators, industry representatives, and scientific experts. The broader objective, according to the government, is to promote the consistent adoption of IP standards not just across Uttarakhand but throughout the country's pharmaceutical sector. Similar outreach initiatives are expected to be held in other major manufacturing clusters as the IP 2026 rollout gathers pace.
Point of View
But quality compliance has not always kept pace with production scale. IP 2026 introduces tighter microbiological and analytical benchmarks, and the gap between what the updated pharmacopoeia demands and what mid-sized manufacturers currently practise is real. Outreach events are necessary but not sufficient — the harder question is whether the IPC has the inspection bandwidth to enforce what it is now promoting. India's global pharma reputation, built on generics exports, is only as strong as its weakest manufacturing cluster.
NationPress
29 Jul 2026
Frequently Asked Questions
What is the Indian Pharmacopoeia 2026 conclave held in Haridwar?
It is a scientific conclave organised by the Indian Pharmacopoeia Commission (IPC) in Haridwar on 11 June 2025 to raise awareness of new provisions under IP 2026 and promote quality compliance across the pharmaceutical manufacturing sector. The event brought together manufacturers, regulators, analytical scientists, and quality professionals from Uttarakhand and beyond.
Why was the conclave held in Haridwar specifically?
Uttarakhand is one of India's leading pharmaceutical manufacturing hubs and has been among the states effectively utilising the IP and Indian Pharmacopoeia Reference Substances. The IPC chose Haridwar to provide direct handholding support to local manufacturers and strengthen compliance with updated pharmacopoeial requirements.
What topics were covered at the IP 2026 conclave?
Technical sessions addressed recent developments in pharmacopoeial standards, reference substances, microbiological quality requirements, quality management systems, analytical investigations, and biological standards. Participants received practical insights into applying IP norms in pharmaceutical manufacturing and quality control.
Who is the Indian Pharmacopoeia Commission (IPC)?
The IPC is an autonomous institution under India's Ministry of Health and Family Welfare responsible for setting and updating pharmacopoeial quality standards for medicines. It publishes the Indian Pharmacopoeia, which defines quality, safety, and efficacy benchmarks for drugs manufactured and sold in India.
What are the broader implications of IP 2026 for the pharma sector?
IP 2026 introduces updated quality standards that pharmaceutical manufacturers across India are expected to adopt. Consistent compliance is critical for India's standing as a global generics supplier, and the IPC's outreach programme aims to ensure manufacturers — particularly in key hubs like Uttarakhand — are equipped to meet the new benchmarks.
